Showing 5211-5220 of 6036 results for "".
- New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercepthttps://modernod.com/news/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-with-beovu-versus-aflibercept/2478080/Novartis announced results of a new post-hoc analysis of Beovu (brolucizumab) phase 3 HAWK and HARRIER pivotal trials demonstrating faster sustainable fluid control when compared with aflibercept in patients with wet
- jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosahttps://modernod.com/news/jcyte-announces-phase-2b-results-of-jcell-therapy-in-retinitis-pigmentosa/2478078/jCyte Inc. announced promising results from a phase 2b clinical trial of jCell in retinitis pigmentosa (RP), irrespective of genetic subtype. jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addi
- Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to RVOhttps://modernod.com/news/aerie-pharmaceuticals-reports-positive-topline-results-for-ar-1105-phase-2-clinical-trial-in-patients-with-macular-edema-due-to-rvo/2478079/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion. AR-1105 Phase 2 Highlights
- Novartis Launches “Not Today, Dry Eye” Consumer Campaignhttps://modernod.com/news/novartis-launches-not-today-dry-eye-consumer-campaign/2478073/This month, Novartis launched its new direct-to-consumer commercial and campaign “Not Today, Dry Eye,” which aims to improve awareness of dry eye disease (DED) among consumers. This campaign underscores the fact that inflammation can play an important role in the development and amplification of
- Pepcid As a Coronavirus Remedy? Trump’s $21-Million Gamble Fizzledhttps://modernod.com/news/pepcid-as-a-coronavirus-remedy-trumps-21-million-gamble-fizzled/2478070/As the coronavirus began its deadly march through the world, two well-respected American doctors identified a possible but seemingly unlikely remedy: Pepcid, the heartburn medication found on drugstore shelves everywhere, according to an Associated
- Maculopathy Tied to Pentosan Polysulfate Sodium May Worsen After Drug Cessationhttps://modernod.com/news/maculopathy-tied-to-pentosan-polysulfate-sodium-may-worsen-after-drug-cessation/2478071/Pentosan polysulfate sodium (PPS)-associated maculopathy may continue for at least 10 years after drug cessation and in some cases may pose a threat to central vision, according to a case report, Reuters reported. The condition 
- Hadley Launches New Website For Those Facing Vision Losshttps://modernod.com/news/hadley-launches-new-website-for-those-facing-vision-loss/2478068/In 1920, William Hadley, a Chicago area high school teacher who lost his sight at the age of 55, revolutionized the way adults facing vision loss would learn to read again when he created his Braille by Mail system. One hundre
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- Aurinia Prices $200 Million Public Offering of Common Shareshttps://modernod.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investig
- MeiraGTx Announces Positive Clinical Data of Investigational Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/meiragtx-announces-positive-clinical-data-of-investigational-gene-therapy-for-x-linked-retinitis-pigmentosa/2478062/MeiraGTx Holdings announced 6-month data from the ongoing phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. Significant improve